Review of effects of anti-VEGF treatment on refractive error

To examine the effect of anti-vascular endothelial growth factor (anti-VEGF) agents on refractive error in the setting of retinopathy of prematurity (ROP) through a review of the literature, a PubMed search was performed of appropriate search terms, and the results of all relevant studies were extracted and compiled. Eleven relevant articles were identified in the literature, totaling 466 eyes, treated with varied anti-VEGF agents (bevacizumab, ranibizumab, and aflibercept) with mean spherical equivalent refractions ranging from +0.75 D to −3.57 D, with prevalence of high myopia ranging from 0 to 35%. Anti-VEGF monotherapy for ROP leads to low levels of myopia, and there may be a differential effect of specific anti-VEGF agents utilized on refractive outcomes.

• Publication year

  2016

• Venue

  Eye and Brain

• Publication date

  2016-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/EB.S99306PMID 28539808PMCID 5398745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity.

  2015cited by this paper
• Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

  2015cited by this paper
• Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy

  2015cited by this paper
• Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.

  2015cited by this paper
• INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY: Comparison Between Ranibizumab and Bevacizumab

  2015influential reference
• Petaloid Macular Edema and Outcomes in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)

  2015cited by this paper
• Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.

  2015cited by this paper
• Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

  2014influential reference
• Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.

  2014influential reference
• Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity

  2014cited by this paper
• Long‐term biometric optic components of diode laser‐treated threshold retinopathy of prematurity at 9 years of age

  2013cited by this paper
• Development of refractive error in individual children with regressed retinopathy of prematurity.

  2013cited by this paper
• Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age.

  2013cited by this paper
• LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up

  2013cited by this paper
• Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

  2013cited by this paper
• An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.

  2013cited by this paper
• Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

  2012cited by this paper
• Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity.

  2012cited by this paper
• Eye size in threshold retinopathy of prematurity, based on a Danish preterm infant series: early axial eye growth, pre- and postnatal aspects.

  2012cited by this paper
• Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡*

  2012cited by this paper
• Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

  2012cited by this paper
• Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

  2012cited by this paper
• Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.

  2012cited by this paper
• Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• Long-term evaluation of refractive status and optical components in eyes of children born prematurely.

  2010cited by this paper
• Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

  2010cited by this paper
• Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)

  2008cited by this paper
• Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age.

  2008cited by this paper
• Pharmacokinetics of intravitreal ranibizumab (Lucentis).

  2007cited by this paper
• Pharmacokinetics of intravitreal bevacizumab (Avastin).

  2007cited by this paper
• Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity.

  2006cited by this paper
• Change of refractive state and eye size in children of birth weight less than 1701 g

  2006cited by this paper
• Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

  2004cited by this paper
• Ocular growth and refractive error development in premature infants with or without retinopathy of prematurity.

  2003cited by this paper
• Ocular growth and refractive error development in premature infants without retinopathy of prematurity.

  2003cited by this paper
• Angle closure in younger patients.

  2003influential reference
• Angle closure in younger patients.

  2003cited by this paper
• Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity.

  2002cited by this paper
• Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development.

  2001cited by this paper
• Does cryotherapy affect refractive error? Results from treated versus control eyes in the cryotherapy for retinopathy of prematurity trial.

  2001cited by this paper
• Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

  1998cited by this paper
• Prevalence of myopia between 3 months and 5 12 years in preterm infants with and without retinopathy of prematurity

  1998cited by this paper
• Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study

  1997cited by this paper
• The course of myopia in children with mild retinopathy of prematurity.

  1995cited by this paper
• Postnatal retinal vascularization in former preterm infants with retinopathy of prematurity.

  1994cited by this paper
• Refractive outcome following diode laser versus cryotherapy for eyes with retinopathy of prematurity.

  1994cited by this paper
• Management of late-onset angle-closure glaucoma associated with retinopathy of prematurity.

  1991influential reference
• Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

  1988cited by this paper
• Myopia in premature babies with and without retinopathy of prematurity.

  1983cited by this paper
• Anterior segment abnormalities in cicatricial retinopathy of prematurity.

  1979cited by this paper

• Corneal aberrations and anterior segment parameters in preterm children with or without a history of retinopathy of prematurity

  2025cites this paper
• A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity

  2025cites this paper
• Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.

  2024cites this paper
• Ocular Biometric and Optical Coherence Tomography Parameters in Former Preterm Children: A Cohort Study

  2024cites this paper
• Long-term outcomes of visual motor integration and motor development children with retinopathy of prematurity

  2024cites this paper
• Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries

  2023cites this paper
• Corneal refractive error and astigmatism in patients aged 6 to 18 years with a history of retinopathy of prematurity and birth weight of <1500 g

  2023cites this paper
• Identifying novel candidate compounds for therapeutic strategies in retinopathy of prematurity via computational drug-gene association analysis

  2023cites this paper
• Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity

  2023cites this paper
• Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity

  2023cites this paper
• Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization

  2022cites this paper
• Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity

  2022cites this paper
• Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review

  2022cites this paper
• Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience.

  2022cites this paper
• Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection

  2022cites this paper
• Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity

  2021cites this paper
• Complications of retinopathy of prematurity treatment

  2021cites this paper
• Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity.

  2021cites this paper
• Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity

  2021cites this paper
• Refractive Outcomes in Infants with Treated or Spontaneously Regressed Retinopathy of Prematurity

  2020cites this paper
• ANATOMICAL AND FUNCTIONAL RESULTS OF INTRAVITREAL AFLIBERCEPT MONOTHERAPY FOR TYPE 1 RETINOPATHY OF PREMATURITY: One-Year Outcomes.

  2020cites this paper
• Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity.

  2020cites this paper
• Comparison of foveal thickness in preschool children with a history of retinopathy of prematurity and laser photocoagulation or anti-vascular endothelial growth factor treatment: a prospective, longitudinal study

  2020cites this paper
• Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis.

  2020cites this paper
• Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP.

  2020cites this paper
• Innovative Approaches in the Delivery of Primary and Secondary Eye Care

  2019cites this paper
• Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP)

  2019cites this paper
• The use of bevacizumab in pediatric retinal and choroidal disease: A review

  2019cites this paper
• Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review

  2019cites this paper
• Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.

  2019cites this paper
• Anti‐Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity

  2018cites this paper
• Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity

  2018cites this paper
• Methodologic Assessment of the Systematic Reviews of Ophthalmic Adverse Drug Reactions Published in Ophthalmology Journals: A Systematic Review

  2018cites this paper
• Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity.

  2018cites this paper
• Langzeiteffekte der Anti-VEGF-Therapie bei Frühgeborenenretinopathie

  2018cites this paper
• Innovative Approaches in the Delivery of Eye Care: Children

  2018cites this paper
• Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP.

  2018cites this paper